6533b81ffe1ef96bd1277126
RESEARCH PRODUCT
Non-invasive cardiovascular imaging for evaluating subclinical target organ damage in hypertensive patients
Francisco AlpenduradaGiuseppe ManciaStefania PaolilloGiovanni De SimoneBryan WilliamsPasquale Perrone-filardiThomas KahanEnrico Agabiti-roseiRedon JosepAntonio CocaRoland E. SchmiederMaurizio GalderisiErwan Donalsubject
cardiovascular riskmedicine.medical_specialtyarterial hypertension[SDV]Life Sciences [q-bio]Population030204 cardiovascular system & hematologyAsymptomatic03 medical and health sciences0302 clinical medicineInternal medicinetarget organ damageMedicineRadiology Nuclear Medicine and imagingIn patient030212 general & internal medicineAdverse effecteducationnon-invasive cardiovascular imagingSubclinical infectioneducation.field_of_studybusiness.industryNon invasiveGeneral MedicineTarget organ damage3. Good healthRisk stratificationCardiologyprognosismedicine.symptomCardiology and Cardiovascular Medicinebusinessdescription
International audience; Arterial hypertension (HTN) accounts for the largest amount of attributable cardiovascular (CV) mortality worldwide, and risk stratification in hypertensive patients is of crucial importance to manage treatment and prevent adverse events. Asymptomatic involvement of different organs in patients affected by HTN represents an independent determinant of CV risk and the identification of target organ damage (TOD) is recommended to further reclassify patients' risk. Non-invasive CV imaging is progressively being used and continues to provide new technological opportunities to TOD evaluation at early stage. The aim of this article is to provide the community of cardiology with an update on appropriate and justified use of non-invasive imaging tests in the growing population of hypertensive patients.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2017-01-01 |